Germany-based Merck KGaA (NYSE: MRK) has agreed to acquire Minneapolis-based Bio-Techne Corporation (Nasdaq: TECH) in an all-cash transaction valued at approximately $11.3Bn (€9.9Bn), representing the science and technology company’s largest acquisition in more than a decade. Under the terms of the definitive merger agreement, Bio-Techne shareholders will receive $73 per share in cash, a 36% premium to the company’s one-month volume-weighted average trading price. The transaction would expand Merck’s life science tools platform across multi-omics, spatial biology, precision diagnostics and cell & gene therapy. The deal, which has been approved by Bio-Techne’s board, is expected to close in late 2026 or early 2027 subject to regulatory and shareholder approvals. For an investment banking audience, the transaction offers a useful read on how large strategic acquirers are deploying capital into life science tooling at a moment when smaller players are facing mounting pressure to consolidate.

Deal Structure and Terms

The transaction is structured as an all-cash purchase at $73 per share, which translates to a total enterprise value of roughly $11.3Bn (€9.9Bn). That figure reflects a 36% premium to Bio-Techne’s one-month volume-weighted average and a premium of approximately 24% to its closing price on the day before the announcement. The consideration is fixed, with no contingent value rights or milestone-based components, which removes much of the post-closing uncertainty that often accompanies life sciences transactions. Closing is expected in late 2026 or early 2027, pending customary regulatory clearances and a vote by Bio-Techne shareholders. The clean structure suggests both parties prioritized certainty of value and execution over a more complex, performance-contingent arrangement.

Company Overview

Bio-Techne is a 50-year-old provider of high-purity recombinant proteins, antibodies, cytokines and multiplex immunoassay platforms used across drug discovery, cell therapy manufacturing and clinical diagnostics. The company generated roughly $1.2Bn in net revenue in fiscal 2024 and employs more than 3,000 people globally. Its business is divided into two segments, with protein sciences accounting for approximately 75% of revenue, and diagnostics & genomics making up the balance. Products such as its Simple Plex and Ella automated protein analysis systems position the company as a critical upstream supplier for biologics development and advanced therapy manufacturing. Within the competitive landscape, Bio-Techne sits alongside larger names such as Thermo Fisher Scientific and Lonza in the recombinant protein and bioprocessing reagents market.

Strategic Rationale

For Merck, the acquisition likely reflects a deliberate move to deepen its presence across the life science value chain rather than a purely opportunistic purchase. The combination adds Bio-Techne’s multi-omics offerings, analytical technologies and integrated workflow solutions to Merck KGaA’s existing platforms in research, bioprocessing and advanced therapeutics. Management has framed the deal as a direct contribution to its mid- to long-term strategy, which emphasizes high-growth value drivers and platformed capabilities. The advanced therapeutics segment, while currently the smallest of Bio-Techne’s served markets, has reportedly been growing at a more than 20% annual rate and may represent the most attractive long-term expansion lane. Read in that light, the transaction appears designed to position the combined business closer to the fastest-moving areas of life sciences demand.

Financing and Credit Considerations

Merck plans to fund the purchase through a combination of cash on hand and newly raised debt, an approach intended to keep its balance sheet within investment-grade territory. The all-cash, fixed-consideration structure gives Bio-Techne shareholders certainty while leaving the acquirer to absorb integration and financing risk. For a deal of this size, the incremental leverage will probably draw scrutiny from rating agencies, though Merck’s management has signaled its intent to preserve a strong credit profile. The absence of contingent value rights also simplifies the post-closing capital picture, since the full purchase price is known at signing. How quickly Merck is able to deleverage after closing may prove relevant to how the market assesses the transaction over time.

Acquisition Track Record

The transaction would be Merck’s largest acquisition since its roughly $17Bn purchase of Sigma-Aldrich, which was announced in 2014 and completed the following year. It extends a long pattern of sizable U.S. acquisitions that includes Millipore for about $7Bn in 2010, Versum Materials for roughly $6.6Bn in 2019 and SpringWorks Therapeutics for $3.9Bn last year. Coming roughly two months after Kai Beckmann assumed the chief executive role, the deal may signal the kind of capital deployment that will define his early tenure. Merck had publicly indicated that it was actively pursuing deals, and Bio-Techne fits its stated preference for sourcing innovation through M&A. Taken together, the acquisition suggests continuity in the company’s appetite for scaled strategic additions rather than a departure from its prior approach.

Market Context

The transaction arrives less than two weeks after activist investor Ananym Capital Management built a stake in Bio-Techne and urged the board to pursue a strategic review, including a potential sale. Bio-Techne shares had fallen well below their 2021 peak, trading at less than half that level before the announcement. The Bio-Techne deal may be read as part of a wider consolidation trend, in which scale, manufacturing reach and global distribution are becoming more decisive competitive factors.

Conclusion

For Bio-Techne shareholders, the all-cash structure offers immediate and certain value at a meaningful premium, which likely explains both the board’s support and the activist investor’s earlier push toward a sale. Regulatory review across multiple jurisdictions and the required shareholder vote remain the primary gating items before the expected close. More broadly, the transaction reinforces the theme that strategic acquirers with strong balance sheets are positioned to consolidate high-quality life science tooling assets while valuations sit below prior peaks. For advisors and investors tracking the sector, Merck’s $11.3Bn commitment to Bio-Techne offers a clear data point on how that consolidation may continue to unfold.

About DelMorgan & Co. (www.delmorganco.com)

With over $300 billion of successful transactions in over 80 countries, DelMorgan‘s Investment Banking professionals have worked on some of the most challenging, most rewarding and highest profile transactions in the U.S. and around the globe. DelMorgan specializes in capital raising and M&A advisor services for companies across all industries and is recognized as one of the leading investment banking practices in California and globally.

Learn more about DelMorgan’s Capabilities, Transactions, and why DelMorgan is ranked as the #1 Investment Bank in Los Angeles and #2 in California by Axial.